Vaithianathan Palaniappan
Technik-/Wissenschafts-/F&E-Leiter bei Flagship Pioneering
Profil
alani Palaniappan joined Flagship Pioneering in 2021 and is Chief Technology Officer of Pioneering Medicines.
In this role, he leads the strategy and implementation of chemistry, manufacturing and controls (CMC) aspects of asset development, ensuring Pioneering Medicines establishes a world-class and cutting-edge technical operations function.
To achieve this, Palani partners with external contract development and manufacturing organizations as well as leaders from bioplatform companies across the Flagship ecosystem to lead CMC, pharmaceutical development, and manufacturing efforts for all programs across Pioneering Medicines’ portfolio.
Palani previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences leading cell and gene therapy development for rare diseases such as sickle cell disease and hypophosphatasia.
His prior executive roles included Head of Global Technical Operations at Sarepta Therapeutics overseeing development of RNA and DNA therapies for neuromuscular and musculoskeletal conditions, and Global Head of Biologics and New Modality Development at Takeda Pharmaceuticals for over a decade focusing on oncology, gastrointestinal and central nervous system diseases where he led teams in Japan and the U.S.
Palani received his Ph.D.
from the Indian Institute of Technology, Kanpur and completed his post-doctoral studies in biochemistry and biophysics at the University of California, Riverside and Virginia Commonwealth University.
He holds a M.S.
and B.S.
from Annamalai University.
He has completed executive leadership education at Oxford University and at Insead.
From 2017 to 2020, Palani served on the Board of the International Consortium for Innovation & Quality (IQ), and from 2016 to 2018 he was IQ’s inaugural Chair of the Biologics CMC Leadership Group.
He also serves on the biotechnology curriculum advisory board at Northeastern University.
Aktive Positionen von Vaithianathan Palaniappan
Unternehmen | Position | Beginn |
---|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2021 |
Ehemalige bekannte Positionen von Vaithianathan Palaniappan
Unternehmen | Position | Ende |
---|---|---|
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Technik-/Wissenschafts-/F&E-Leiter | 02.11.2021 |
SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 02.05.2020 |
International Consortium for Innovation & Quality | Vorsitzender | - |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | 02.01.2018 |
Ausbildung von Vaithianathan Palaniappan
Indian Institute of Technology Kanpur | Doctorate Degree |
Annamalai University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SAREPTA THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Aruvant Sciences, Inc.
Aruvant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Aruvant Sciences, Inc. operates as a clinical-stage biopharmaceutical company. The firm develops and commercializes gene therapies for hematological diseases utilizing reduced-intensity conditioning. It's lead candidate ARU-1801, is a modified fetal hemoglobin gene therapy for sickle cell disease and related hemoglobinopathies. The company is headquartered in New York, NY. | Health Technology |
International Consortium for Innovation & Quality | |
Takeda Pharmaceuticals U.S.A., Inc.
Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |